Skip to main content
Top
Published in: Calcified Tissue International 6/2009

01-12-2009

The Heterozygous Lemd3 +/GT Mouse Is Not a Murine Model for Osteopoikilosis in Humans

Authors: Annelies Dheedene, Steven Deleye, Jan Hellemans, Steven Staelens, Stefaan Vandenberghe, Geert Mortier

Published in: Calcified Tissue International | Issue 6/2009

Login to get access

Abstract

Osteopoikilosis and the Buschke-Ollendorff syndrome are skeletal dysplasias with hyperostotic lesions in the long bones. These disorders are caused by heterozygous loss-of-function mutations in the LEMD3 gene. LEMD3 codes for a protein of the inner nuclear membrane that, through interaction with R-SMADs, antagonizes the BMP and TGFβ1 pathway. It is suggested that the hyperostotic lesions in these disorders are caused by enhanced BMP and TGFβ1 signaling. The exact mechanism by which mutations in the LEMD3 gene lead to these bone lesions has not yet been unraveled precisely. To further assess this, an Lemd3 gene–trapped mouse was created in a gene-trapping program by Baygenomics. To investigate whether the heterozygous gene-trapped mouse is a good model for osteopoikilosis in humans, we studied these mice radiologically with high-resolution micro-computed tomography (microCT) and histologically. X-ray images were evaluated by a trained radiologist, but no typical osteopoikilosis lesions could be recognized. On all microCT reconstructed images a 3D cortical and trabecular quantitative analysis was performed, investigating different histomorphometric parameters ranging from percent bone volume, bone surface/volume ratio over trabecular thickness, separation, number, and pattern factor to structure model index and fractal dimension. No significant differences were found after a t-test statistical analysis. Also, histological analysis did not reveal lesions typical for osteopoikilosis. We conclude that the heterozygous Lemd3 gene–trapped mouse is not a good model to study osteopoikilosis and the Buschke-Ollendorff syndrome.
Literature
1.
go back to reference Lagier R, Mbakop A, Bigler A (1984) Osteopoikilosis: a radiological and pathological study. Skeletal Radiol 11:161–168CrossRefPubMed Lagier R, Mbakop A, Bigler A (1984) Osteopoikilosis: a radiological and pathological study. Skeletal Radiol 11:161–168CrossRefPubMed
2.
go back to reference Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, Savarirayan R, Van Hul W, Vanhoenacker F, Huylebroeck D, De Paepe A, Naeyaert JM, Vandesompele J, Speleman F, Verschueren K, Coucke PJ, Mortier GR (2004) Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 36:1213–1218CrossRefPubMed Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, Savarirayan R, Van Hul W, Vanhoenacker F, Huylebroeck D, De Paepe A, Naeyaert JM, Vandesompele J, Speleman F, Verschueren K, Coucke PJ, Mortier GR (2004) Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 36:1213–1218CrossRefPubMed
3.
go back to reference Paulin-Levasseur M, Blake DL, Julien M, Rouleau L (1996) The MAN antigens are non-lamin constituents of the nuclear lamina in vertebrate cells. Chromosoma 104:367–379CrossRefPubMed Paulin-Levasseur M, Blake DL, Julien M, Rouleau L (1996) The MAN antigens are non-lamin constituents of the nuclear lamina in vertebrate cells. Chromosoma 104:367–379CrossRefPubMed
4.
go back to reference Lin F, Blake DL, Callebaut I, Skerjanc IS, Holmer L, McBurney MW, Paulin-Levasseur M, Worman HJ (2000) MAN1, an inner nuclear membrane protein that shares the LEM domain with lamina-associated polypeptide 2 and emerin. J Biol Chem 275:4840–4847CrossRefPubMed Lin F, Blake DL, Callebaut I, Skerjanc IS, Holmer L, McBurney MW, Paulin-Levasseur M, Worman HJ (2000) MAN1, an inner nuclear membrane protein that shares the LEM domain with lamina-associated polypeptide 2 and emerin. J Biol Chem 275:4840–4847CrossRefPubMed
5.
go back to reference Wagner N, Krohne G (2007) LEM-domain proteins: new insights into lamin-interacting proteins. Int Rev Cytol 261:1–46CrossRefPubMed Wagner N, Krohne G (2007) LEM-domain proteins: new insights into lamin-interacting proteins. Int Rev Cytol 261:1–46CrossRefPubMed
6.
go back to reference Lin F, Morrison JM, Wu W, Worman HJ (2005) MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. Hum Mol Genet 14:437–445CrossRefPubMed Lin F, Morrison JM, Wu W, Worman HJ (2005) MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. Hum Mol Genet 14:437–445CrossRefPubMed
7.
go back to reference Pan D, Estevez-Salmeron LD, Stroschein SL, Zhu X, He J, Zhou S, Luo K (2005) The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor-β superfamily of cytokines. J Biol Chem 280:15992–16001CrossRefPubMed Pan D, Estevez-Salmeron LD, Stroschein SL, Zhu X, He J, Zhou S, Luo K (2005) The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor-β superfamily of cytokines. J Biol Chem 280:15992–16001CrossRefPubMed
8.
go back to reference Ishimura A, Ng JK, Taira M, Young SG, Osada S (2006) Man1, an inner nuclear membrane protein, regulates vascular remodeling by modulating transforming growth factor beta signaling. Development 133:3919–3928CrossRefPubMed Ishimura A, Ng JK, Taira M, Young SG, Osada S (2006) Man1, an inner nuclear membrane protein, regulates vascular remodeling by modulating transforming growth factor beta signaling. Development 133:3919–3928CrossRefPubMed
9.
go back to reference Cohen TV, Kosti O, Stewart CL (2007) The nuclear envelope protein MAN1 regulates TGFbeta signaling and vasculogenesis in the embryonic yolk sac. Development 134:1385–1395CrossRefPubMed Cohen TV, Kosti O, Stewart CL (2007) The nuclear envelope protein MAN1 regulates TGFbeta signaling and vasculogenesis in the embryonic yolk sac. Development 134:1385–1395CrossRefPubMed
10.
go back to reference Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef
11.
go back to reference Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105:1085–1093CrossRefPubMed Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105:1085–1093CrossRefPubMed
12.
go back to reference Liu J, Lee KK, Segura-Totten M, Neufeld E, Wilson KL, Gruenbaum Y (2003) MAN1 and emerin have overlapping function(s) essential for chromosome segregation and cell division in Caenorhabditis elegans. Proc Natl Acad Sci USA 100:4598–4603CrossRefPubMed Liu J, Lee KK, Segura-Totten M, Neufeld E, Wilson KL, Gruenbaum Y (2003) MAN1 and emerin have overlapping function(s) essential for chromosome segregation and cell division in Caenorhabditis elegans. Proc Natl Acad Sci USA 100:4598–4603CrossRefPubMed
13.
go back to reference Callewaert BL, Loeys BL, Casteleyn C, Willaert A, Dewint P, De Backer J, Sedlmeier R, Simoens P, De Paepe AM, Coucke PJ (2008) Absence of arterial phenotype in mice with homozygous slc2A10 missense substitutions. Genesis 46:385–389CrossRefPubMed Callewaert BL, Loeys BL, Casteleyn C, Willaert A, Dewint P, De Backer J, Sedlmeier R, Simoens P, De Paepe AM, Coucke PJ (2008) Absence of arterial phenotype in mice with homozygous slc2A10 missense substitutions. Genesis 46:385–389CrossRefPubMed
14.
go back to reference Rosati R, Horan GS, Pinero GJ, Garofalo S, Keene DR, Horton WA, Vuorio E, de Crombrugghe B, Behringer RR (1994) Normal long bone growth and development in type X collagen-null mice. Nat Genet 8:129–135CrossRefPubMed Rosati R, Horan GS, Pinero GJ, Garofalo S, Keene DR, Horton WA, Vuorio E, de Crombrugghe B, Behringer RR (1994) Normal long bone growth and development in type X collagen-null mice. Nat Genet 8:129–135CrossRefPubMed
15.
go back to reference Aszodi A, Bateman JF, Hirsch E, Baranyi M, Hunziker EB, Hauser N, Bosze Z, Fassler R (1999) Normal skeletal development of mice lacking matrilin 1: redundant function of matrilins in cartilage? Mol Cell Biol 19:7841–7845PubMed Aszodi A, Bateman JF, Hirsch E, Baranyi M, Hunziker EB, Hauser N, Bosze Z, Fassler R (1999) Normal skeletal development of mice lacking matrilin 1: redundant function of matrilins in cartilage? Mol Cell Biol 19:7841–7845PubMed
Metadata
Title
The Heterozygous Lemd3 +/GT Mouse Is Not a Murine Model for Osteopoikilosis in Humans
Authors
Annelies Dheedene
Steven Deleye
Jan Hellemans
Steven Staelens
Stefaan Vandenberghe
Geert Mortier
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9305-z

Other articles of this Issue 6/2009

Calcified Tissue International 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.